Login to Your Account



Regeneron 'mountain' gene therapy effort in potential $640M eye deal with Avalanche

By Randy Osborne
Staff Writer

Monday, May 5, 2014
As investors await Regeneron Pharmaceuticals Inc.'s first quarter earnings, the company disclosed an ophthalmology deal with gene therapy specialist Avalanche Biotechnologies Inc. that buys a time-limited right to first negotiations to phase II-stage AVA-101, targeting VEGF for wet AMD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription